10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Synthesis of 5-isoxazol-5-yl-2′-deoxyuridines exhibiting antiviral activity against HSV and several RNA viruses

      brief-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Graphical abstract

          Novel nucleosides were designed and synthesized by [3+2] cycloaddition, and showed moderate antiviral activities. The nucleosides were tested against 12 different viruses.

          Abstract

          This paper describes a simple method for synthesizing a small library of 5-isoxazol-5-yl-2′-deoxyuridines from 5-iodo-2′-deoxyuridine. Nitrile oxides were generated in situ from oximes using a commercial bleaching agent; their cycloaddition with 5-ethynyl-2′-deoxyuridine yielded isoxazoles possessing activity against herpes simplex viruses 1 and 2, Encephalomyocarditis virus, Coxsackie B3, and vesicular stomatitis virus; these isoxazoles were, however, inactive against corona virus, influenza virus, and HIV.

          Related collections

          Author and article information

          Contributors
          Journal
          Bioorg Med Chem Lett
          Bioorg. Med. Chem. Lett
          Bioorganic & Medicinal Chemistry Letters
          Published by Elsevier Ltd.
          0960-894X
          1464-3405
          31 December 2008
          15 February 2009
          31 December 2008
          : 19
          : 4
          : 1126-1128
          Affiliations
          Department of Chemistry, BK School of Molecular Science, Pohang University of Science and Technology, Pohang 790-784, South Korea
          Author notes
          [* ]Corresponding author. Tel.: +82 54 279 2115; fax: +82 54 279 3399. bhkim@ 123456postech.ac.kr
          Article
          S0960-894X(08)01623-5
          10.1016/j.bmcl.2008.12.103
          7126966
          19147352
          f33bac25-f5b5-49e9-87aa-5d7d98d45a17
          Copyright © 2009 Published by Elsevier Ltd.

          Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

          History
          : 8 October 2008
          : 5 December 2008
          : 26 December 2008
          Categories
          Article

          Pharmaceutical chemistry
          hsv,antiviral,emcv,cox. b3,vsv,isoxazole,isoxazole nucleosides,antiviral nucleoside,[3+2] cycloaddition

          Comments

          Comment on this article